AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC)

This early-phase trial is testing a new type of cell therapy called AB-3028 — engineered immune cells designed to attack prostate cancer — in men with advanced prostate cancer that has stopped responding to hormone therapy (called castration-resistant prostate cancer). **You may be eligible if...** - You are 18 or older with confirmed advanced prostate cancer - Your cancer has continued to grow despite hormone-lowering treatment (castration-resistant) - You have already tried at least one hormonal therapy (ARPI) - Your cancer tests positive for PSMA (a protein found on prostate cancer cells) - You have measurable disease on imaging or a rising PSA - Your organ function is adequate **You may NOT be eligible if...** - You have received systemic prostate cancer therapy within 14 days before the scheduled cell collection procedure - You have cancer that has spread to the brain or spinal fluid - You have other serious medical conditions that would interfere with treatment Talk to your doctor to see if this trial is right for you.